GlassScriptPhysician profile
Steven M Taormina
NPI 1134111065
$9,186.02
in general payments reported to CMS, 2019-2025
44 companies · $1,957 in 2025
The $1,957 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $247 · 2021: $695 · 2022: $1,739 · 2023: $1,593 · 2024: $2,139 · 2025: $1,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,688.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,002.89 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $920.19 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $886.92 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $851.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.84 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $656.15 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $591.14 | 2019-2025 | Repatha, Prolia, Otezla |
| Pfizer INC. | $570.16 | 2019-2025 | |
| Exact Sciences Corporation | $479.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $284.21 | 2019-2025 | Capvaxive, Gardasil 9, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.93 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $186.40 | 2019-2023 | |
| Glaxosmithkline, LLC. | $164.30 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $133.65 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $101.11 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Taormina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.